News Quantified

PSTV – plus therapeutics, inc. (US:NASDAQ)

Stock Stats

News Stats

Order Stats

News

Plus Therapeutics Appoints Randy H. Goodman, PhD, MHA, as Vice President of Value Strategy & HEOR to Advance Market Access and Commercial Execution

Plus Therapeutics (PSTV) had its price target lowered by Ascendiant Capital Markets from $475.00 to $65.00. They now have a "buy" rating on the stock.

Plus Therapeutics Appoints Eric J. Daniels, M.D., MBA, as Chief Development Officer to Advance Clinical Pipeline

Plus Therapeutics Granted U.S. FDA Orphan Drug Designation to REYOBIQ™ in Pediatric Malignant Gliomas

Plus Therapeutics Receives AMA PLA Code for CNSide® CSF Tumor Cell Enumeration Test, Advancing Reimbursement and U.S. Commercial Adoption

14.6%

BEAT

28.2%

MISS

Ascendiant Capital

Lake Street Capital

Form 8-K PLUS THERAPEUTICS, INC. For: Apr 08

Form 8-K PLUS THERAPEUTICS, INC. For: Apr 08

Form 8-K PLUS THERAPEUTICS, INC. For: Apr 01

Form 4 PLUS THERAPEUTICS, INC. For: Apr 01 Filed by: HEDRICK MARC H

Form 4 PLUS THERAPEUTICS, INC. For: Apr 01 Filed by: Sims Andrew John Hugh MacIntyre

Top News Gainers

8/15 Q2/2019 6/30/2019 EPS -5.120 ZacksConsensus N/A ActVsEst N/A - N/A 272.2%

3/30 Form 8-K PLUS THERAPEUTICS, INC. For: Mar 29 57.6%

8/26 Form SC 13G PLUS THERAPEUTICS, INC. Filed by: Sassicaia Capital Advisers LLC 44.6%

11/14 Plus Therapeutics Reports Third Quarter 2019 Financial and Business Results 17.8%

10/15 Form 8-K PLUS THERAPEUTICS, INC. For: Oct 09 10.0%

4/6 Plus Therapeutics Donates Personal Protective Equipment to Scripps Health to Confront COVID-19 Pandemic 9.0%

12/9 Plus Therapeutics to Present at Biotech Showcase 2020 7.4%

9/26 Plus Therapeutics, Inc. Announces Closing of $15 Million Underwritten Public Offering 6.1%

1/6 Plus Therapeutics Shareholder Update: Transition Achieved in 2019; Poised for Expansion in 2020 5.0%

11/4 Plus Therapeutics To Report Fiscal 2019 Third Quarter Financial Results and Corporate Update on November 14, 2019 4.4%

Top News Decliners

3/12 Form 8-K PLUS THERAPEUTICS, INC. For: Mar 09 -23.6%

8/2 Form 8-K CYTORI THERAPEUTICS, For: Aug 01 -21.6%

3/30 Form 10-K PLUS THERAPEUTICS, INC. For: Dec 31 -20.0%

8/14 Form NT 10-Q PLUS THERAPEUTICS, INC. For: Jun 30 -19.7%

8/21 Plus Therapeutics: Prepare For The Imminent Dilution [Seeking Alpha] -18.5%

7/29 Plus Therapeutics, Inc. Announces Nasdaq Ticker Symbol Changes and Reverse Stock Split -15.0%

9/16 Form S-1/A PLUS THERAPEUTICS, INC. -14.5%

4/1 Plus Therapeutics Announces Dr. Gregory Stein as Head of Clinical Development -13.3%

9/24 Form 424B4 PLUS THERAPEUTICS, INC. -13.2%

8/9 Form 8-K PLUS THERAPEUTICS, INC. For: Aug 09 -12.5%

Live Event: How Top Hedge Funds Use News To Make Money From The Stock Market & How Ordinary People Are Copying Their Strategies

If you could use the news to make money from the stock market, would you? Join us on our live online event where you’ll discover this simple scientific method that has allowed ordinary people get a huge return from the stock market without excessive risk.

Click Here To Register For The Live Online Workshop

In short, News Quantified specializes in matching financial news with market data. We've analyzed 10s of millions of news events and know exactly which ones have an outsized impact on stock prices. So every single time a news item is released we know exactly what the average effect will be on a particular stock.

Latest Posts

Trading the Google Earnings Announcement: A Strategic Preview

Earnings Week Wrap-up and Takeaways

Earnings Season: Q3 Review, Q4 Kickoff – Morgan Stanley, Bank of America, Goldman Sachs, Netflix

Guerrilla Learning Opportunity: Wealth365 Conference Featuring News Quantified Founder and Much More

The Smart Way to Ten Minutes Per Day